Ensure accurate tumor detection
October is breast cancer awareness month. Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. 1 in 8 women will be diagnosed in their lifetime and there have been over 2 million new cases worldwide in 2018.
For diagnostic and therapeutic purposes, breast cancer tumor markers need to be monitored to inform medical professionals on disease status. However, individual cancer markers are not highly specific on their own as they are sometime expressed and secreted by other cells. Therefore, it is important to assay for a combination of different markers and/or different forms of the same marker to ensure accurate tumor detection and management.
Medix Biochemica’s premium-quality MedixMAB™ monoclonal antibodies and MedixAntigens™ are manufactured using optimized, serum and protein free, industrial-scale in vitro production methods – guaranteeing quality, reliability and batch-to-batch consistency.
We have a range of antibodies for cancer detection and management, including several antibodies to detect cancer antigen 15-3 (CA15-3), a well-characterized serum marker for breast cancer, as well as cancer antigen 125 (CA125), carcinoembryonic antigen (CEA) and human epididymis protein 4 (HE4).
Contact us to today to discover how our antibodies can ensure accurate, reliable results in your cancer assays.
You can also download our technical note to discover our tumor markers range.